MET and non-small cell lung carcinoma: In a phase 2 study of onartuzumab, patients whose NSCLC tissue scored as positive for MET protein by immunohistochemistry (IHC) experienced a significant benefit from treatment with onartuzumab plus erlotinib vs. erlotinib alone.